Article Information
History
- July 15, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Danuta M Skowronski1,2,*,
- Inna Sekirov3,4,
- Suzana Sabaiduc3,
- Macy Zou5,
- Muhammad Morshed3,4,
- David Lawrence3,
- Kate Smolina2,5,
- May A Ahmed1,
- Eleni Galanis1,2,
- Mieke N Fraser5,
- Mayank Singal1,2,
- Monika Naus1,2,
- David M Patrick1,2,
- Samantha E Kaweski3,
- Christopher Mill6,7,
- Romina C Reyes4,8,
- Michael T Kelly4,8,
- Paul N Levett3,4,
- Martin Petric3,4,
- Bonnie Henry2,9 and
- Mel Krajden3,4
- 1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
- 2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
- 3BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada
- 4University of British Columbia, Dept. of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
- 5BC Centre for Disease Control, Data and Analytic Services, Vancouver, British Columbia, Canada
- 6Public Health Agency of Canada, Health Security Infrastructure Branch, Canadian Public Health Service, Vancouver, British Columbia, Canada
- 7BC Centre for Disease Control, Clinical Prevention Services, Vancouver, British Columbia, Canada
- 8LifeLabs, Department of Microbiology, Surrey, British Columbia, Canada
- 9Office of the Provincial Health Officer, Ministry of Health, Victoria, British Columbia, Canada
- ↵*Corresponding Author:
Danuta M Skowronski MD, FRCPC, 655 West 12th Avenue, Vancouver, British Columbia, Canada V5Z 4R4, Ph: 604-707-2511, E-mail: danuta.skowronski{at}bccdc.ca
Posted July 15, 2020.
Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020
